Urology, Urologic Oncology & Radiation Therapy MSO Consolidation
Integrate clinical urology suites with linear accelerator (LINAC) radiation oncology, in-house pathology, and surgical ASCs to capture 13x–16x institutional EBITDA valuations.
Urology is an elite healthcare private equity investment sector due to aging male demographics (prostate cancer, benign prostatic hyperplasia, kidney stones) and unmatched ancillary service potential. Large urology groups consolidated under LUGPA (Large Urology Group Practice Association) models generate massive enterprise value by owning linear accelerators (LINACs) for prostate radiation therapy, advanced CT/ultrasound imaging, in-office pathology labs, and surgical ASCs for robotic and endoscopic procedures. However, high-capital radiation oncology equipment leases and complex Stark Law Designated Health Services (DHS) rules require sophisticated governance. Kompanie LLP architects legally impervious urology MSOs that maximize platform multiple arbitrage.
Deliverables
- Turnkey Urology Friendly PC corporate governance documentation.
- Stark-compliant Radiation Oncology Facility Management Agreement.
- Multi-specialty physician compensation model compliant with CMS rules.
- Linear Accelerator equipment lease structuring and debt financing advisory.
Execution phases
- Stage 1: Ancillary Revenue & DHS Stark Audit — Audit physician compensation formulas, verify LINAC radiation technical component revenues, and inspect pathology lab legal structures.
- Stage 2: Dual-Specialty Governance Structuring — Design balanced governance charters linking urologists and radiation oncologists with Stark-compliant non-referral profit pools.
- Stage 3: Regional Platform Expansion & OEC Addition — Tuck in regional solo urologists, integrate advanced imaging hubs, and prepare institutional data room for secondary sale.
Diligence red flags
- Physician compensation formula distributing linear accelerator radiation profits based on individual prostate cancer biopsy referral numbers.
- LINAC radiation facility operating in an off-site commercial building that fails the CMS Centralized Building 24/7 exclusive space test.
- In-office specialty pharmacy dispensing high-cost oral oncolytics without verified Board of Pharmacy retail licensure.
- High partner-level friction between surgical urologists and non-surgical radiation oncologists over equity distributions.
Frequently asked questions
Can a urology group legally own and operate a radiation oncology linear accelerator (LINAC)?
Yes, provided the group practice satisfies the Stark Law In-Office Ancillary Services Exception (IOASE), including the Group Practice unified business definition and the Same Building or Centralized Building requirement.
What is the multiple lift when a urology group adds radiation therapy and pathology?
Adding a compliant radiation oncology center and histology lab typically expands normalized practice EBITDA by 60% to 110%, while expanding exit multiples from 5x–7x to 13x–16x at institutional recapitalization.